Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
By D. Winkler, M. Sutherland, James C. Geoghegan, Changpu Yu, T. Hayes, J. Skonier, D. Shpektor, M. Jonas, Brian R. Kovacevich, K. Staehling‐Hampton and 3 more. EMBO Journal, 2003
1,137 citations recorded by the source corpus.
Subfields: Molecular Biology, Oncology
View Paper: https://www.semanticscholar.org/paper/6bcd19b59a415255ff913a8ccab69f98d9eba77f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
- J. Smolen
- Cristina Cruciat
- K. Redlich
- G. Mundy
- Christof Niehrs
- Brian K. Hall
- M. Kneissel
- L. Bonewald
In Oncology
Citations in the corpus
- Bone Morphogenetic Proteins (2004, background): “Expression of sclerostin in multipotent fibroblast C3H10T1/2 cells blocks osteoblast differentiation and over-expression of sclerostin in osteoblasts under the control of the osteocalcin promoter in transgenic mice causes osteoporosis (Winkler et al., 2003).”
- Buried alive: How osteoblasts become osteocytes (2006, background): “…sclerostin, Fgfr2c, matrix metalloproteases, and glucocorticoids) that have an impact on osteoblast apoptosis and/or activity (Babij et al 2003; Winkler et al., 2003; Eswarakumar et al., 2004; Karsdal et al., 2004; O’Brien et al., 2004) and thus indirectly on the decision process to become an…”
- Osteoblast-Osteoclast Interactions (2017, background): “(53) showed that no expression of SOST RNA was observed in human osteoclasts or human osteoclast progenitor cells.”
- SOST is a target gene for PTH in bone. (2005, background): “The difficulty to identify a bone cell line that would robustly express SOST is not surprising in the light of the finding that SOST is only expressed in mineralizing osteoblasts, but not in undifferentiated osteoblasts or mesenchymal stem cells (MSCs) [27,28].”
- Secreted and transmembrane wnt inhibitors and activators. (2013, background): “In cell culture models Wise and SOST inhibit BMP signaling (Laurikkala et al. 2003; Winkler et al. 2003); however, the physiological role of this inhibition is still unclear.”
- Sclerostin Mediates Bone Response to Mechanical Unloading Through Antagonizing Wnt/β‐Catenin Signaling (2009, background): “Sclerostin was originally designated as an antagonist of BMP signaling for its binding with BMPs and its inhibition on BMP-induced osteogenesis in in vitro experiments.((16,17)) Although more recent evidence showed it was more likely to be an antagonist of Wnt/b-catenin signaling, no in vivo data we”
- Inflammatory bone loss: pathogenesis and therapeutic intervention (2012, background): “Sclerostin represents another inhibitor of osteoblast activation by interfering with the WNT signalling pathway but also by binding to and antagonizing BMP”